Clinical Trial Notification Program for Scleroderma Patients
Back in February, researchers presented a study investigating the therapeutic effect of the monoclonal antibody CM-101 in animal models of systemic sclerosis (SSc) and idiopathic pulmonary fibrosis (IPF).
Many readers of Scleroderma News have reached out and urged us to do more to bring additional awareness about clinical trials applicable to the scleroderma patient community.
In response, we have created a new Clinical Trial Notification Program that helps us match individuals directly to relevant clinical trials based off of their profile information.
Scleroderma News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.